Evidence map›Paper›PMID 41333213›Full record

ArticleFrontiers in oncology2025

Immunotherapy monotherapy for patients with recurrent nonmetastatic larynx cancer who refuse salvage total laryngectomy.

Courtney Brooke Shires, Merry E Sebelik

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Courtney Brooke ShiresWest Cancer Center, Germantown, TN, United States.
Merry E SebelikDepartment of Otolaryngology, Emory University, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives/Hypothesis: Total laryngectomy has traditionally been recommended for patients with recurrent larynx cancer after radiation or chemoradiation. Some patients refuse salvage surgery. Historically, these patients have been placed on hospice or palliative chemotherapy. Immunotherapy has recently added another treatment modality to our armamentarium. Methods: 8 patients with recurrent larynx cancer declined salvage laryngectomy. They were started on immunotherapy alone. We recorded their demographics, initial cancer stage, initial cancer treatment, combined positive score (CPS) values, need for tracheostomy, addition of chemotherapy to their immunotherapy, and response to therapy. Results: 62.5% were African American, while 37.5% were Caucasian. Most had early (stage 1 or 2 disease) at the time of initial diagnosis. 75% had radiation alone as their initial treatment, while 25% had chemoradiation. All of these patients had high CPS scores. 37.5% progressed on 4 rounds of immunotherapy and are deceased. Chemotherapy was added to the regimen of 50% of the patients after poor response to immunotherapy. 75% of these patients are all still alive after 1 year of treatment. 75% of all patients needed tracheostomy while on salvage treatment. One patient (12.5%) has had a long-lasting positive response to immunotherapy alone. Conclusions: Our patients with nonmetastatic recurrent larynx cancer were found to have high CPS scores, which suggests favorable response to immunotherapy. Most patients with recurrent larynx cancer on immunotherapy required a tracheostomy. These patients had poor response on immunotherapy alone, but had prolonged survival with added chemotherapy. Salvage laryngectomy is the only curative option for these patients, but for those patients that refuse surgery, chemotherapy with immunotherapy has better results than immunotherapy alone. Our results reveal a possible clinical phenomenon, which needs to be confirmed by large sample studies.

Indexed as

cervical metastasishead and neck cancerimmunotherapylaryngectomylarynx cancerprognosisrecurrencesquamous cell carcinoma

Identifiers

PMID41333213
PMCPMC12665598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.